Tomahawk, WI 11/27/2013 (BasicsMedia) – Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has made such a name for itself in terms of manufacturing some of the world’s best weight loss drugs. The company is only one of the major manufactures of weight loss drugs that continuously seek the approval from Food and Drug Administration of the U.S to check if they meet the strict standards required of any drug designed for human consumption. ARNA forwarded a few samples to FDA for trial and approval, as required by the law between 2010 and 2011, and these were rejected.

The approval process is quite lengthy and costly to any drug company, regardless of its size and scope of business. Lately, the company had submitted its latest obesity drug, Belviq to the FDA for approval. Many analysts had started murmuring whether Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) had the capacity to go through another rejection from FDA, and if they could afford to wait any longer to submit Belviq, or any other sample to this federal department for testing. There is no doubting the fact that if this had happened, it would have caused substantial strain on ARNA’s resources.

Three drug companies made their submissions to FDA for approval. These three companies include ARNA, VIVUS and Orexigen, which submitted the following drugs to FDA for approval; Belviq, Qsymia and Contrave respectively. FDA and DEA were concerned that Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s Belviq had the highest chance of being abused by patients taking drugs or medication to overcome problems linked to obesity. Consequently, it had to wait for a while before being granted the approval it sought; way after Qsymia had already made an entry into the market.

Compared to Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Orexigen had a more troubling moment in front of FDA. The FDA raised pertinent issues regarding the ability of Contrave, which is Orexigen’s drug designed to fight the effects of obesity, had the capacity to cause or hasten heart related problems. This has prevented Contrave from getting the approval it sough from FDA, since it has never been cleared since Orexigen was first denied the opportunity to proceed with its production. Unlike ARNA, which has already introduced Belviq into the market, Orexigen will have to wait a little longer.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s obesity drug, Belviq, has not had the impact that the company hoped it would have in the market upon its launch. This fate is shared equally between Belviq and Qsymia. It is not that the drugs are not effective, but the problem seems to lie more with doctors, who are unwilling to prescribe any obesity drug to their patients, regardless of what FDA says. Since these drugs entered the market quite late, doctors are yet to be convinced about their potency levels, hence their preference of the earlier drugs to the recent ones.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) needs to market its latest obesity drug better to highlight the major selling points and advantages that this drug has over its peers. Doctors need to be convinced that ARNA’s Belviq is not in the same class or category as other obesity drugs that took the market by storm only to end up creating more problems than they were supposed to solve.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.